We Are Crinetics

Crinetics is a pharmaceutical company founded in endocrinology research. Our intense focus is on developing much-needed therapies for people with endocrine diseases and endocrine-related tumors. For us, it’s all about these underserved patients, who are eager to find therapies that provide effective disease control and bring more simplicity to their lives. To better achieve these goals, we also partner with endocrinologists and other healthcare practitioners to ensure we’re solving real problems for them.

An Entire Pipeline of Progress

Intellectual rigor, sound science, and innovative approaches are the hallmarks of our work and the way we maintain a healthy pipeline.

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and more:

Our once-daily, oral, investigational drug for the treatment of acromegaly is in Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.

See the science >

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1, 2)
Carcinoid Syndrome
Congenital Hyperinsulinism (Congenital HI)
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity

Our Research

Paltusotine

ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients with Acromegaly.
Monica R. Gadelha, MD, PhD; Murray B. Gordon, MD; Mirjana Doknic, MD, PhD; et al.
Article: The Journal of Clinical Endocrinology & Metabolism, 2022

Learn more about paltusotine

CRN04894

CRN04894: An Oral, Nonpeptide ACTH (MC2) Receptor Antagonist Decreased Basal and Stimulated Cortisol Secretion in Healthy Volunteers
Peter J. Trainer, MD1; Christine T. Ferrara-Cook, MD, PhD1; Alejandro Ayala, MD1; Rosa Luo, MS1; Stephanie Miller, BA1; Yang Wang, MSPH1; Martha Hernandez-Illas, MD2; R. Scott Struthers, PhD1; Stephen F. Betz, PhD1; Alan Krasner, MD1
1Crinetics Pharmaceuticals, Inc., San Diego, CA, USA; 2QPS Miami, Miami, FL, USA

Learn more about CRN04894

Contact Us

Please fill out and submit this form and a member of our Medical Sciences team will contact you directly.

We Are Here For the Patients

To us, patients are more than the symptoms they have or the treatments they’re on. You are partners in this work. Real people with friends and families…ideas and insights…hobbies and hopes. Most of all, you have important contributions to make as we pursue solutions that will impact your life. That’s why we pledge to bring five key qualities to every patient relationship:

rick copy uai

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Watch Patients Talk About Acromegaly

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Watch Patients Talk About Acromegaly